USP offers support for WHO’s biological qualifier plan

By Zachary Brennan contact

- Last updated on GMT

USP offers support for WHO’s biological qualifier plan

Related tags: Manufacturing

USP (US Pharmacopeia) is offering its support for efforts from the WHO to develop a global approach to the naming of all biologics.

The biological qualifier proposal​ from the WHO would add a unique four letter code to a biological active substance manufactured at a specific site. Separate from the INN (International Nonproprietary Name), the BQ code would aim to complement an INN by identifying both the manufacturer and manufacturing site of the active substance.

Because of their structural complexity, the complexity of their manufacturing processes using living organisms, the greater difficulties in achieving consistency of manufactured batches and the often complex long-term effects of their administration to a patient, bioequivalence cannot be easily established for a product containing a biological substance​,” the WHO says in its July proposal.

USP Reaction

USP says in its comment​ on the BQ proposal that it’s “very supportive​” of the plan “and in particular the principle that the BQ should apply to all biologics​” as it considers finding “a broadly agreed upon solution that is built on and consistent with existing, accepted scientific principles critical to supporting a globally relevant approach to the quality assessment of biologicals​.”

USP “considers it essential that the BQ is not part of the nonproprietary name itself, meaning that the BQ would also not be considered part of any applicable compendial name​.

This will allow consistency with currently applied approaches and not disturb existing precedent where multiple non-interchangeable biologics share the same compendial name and monograph specifications, for example Glucagon and Somatropin​,” USP says.

The group also says that the BQ should not be a part of the INN “in order to assure consistency with currently applied compendial approaches​.”

USP’s Role

While USP has expert representation in both INN and USAN (United States Adopted Names Council) deliberations when drugs are given their names very early in their development, USP’s official role in naming “usually does not come into play until much later in the lifecycle of a licensed drug, when a monograph is developed​,” the pharmacopeia says.

Related news

Related products

show more

Microaerobic Fermentation of Lactobacillus acidophilus

Microaerobic Fermentation of Lactobacillus acidophilus

Eppendorf for Bioprocess – Solutions that grow with you | 01-Oct-2019 | Application Note

We successfully performed microaerobic fermenta¬tion of a probiotic strain, Lactobacillus acidophilus, at a very low oxygen level, representing the natural...

Removing Aggregates of an Acidic Monoclonal Antibody

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....

Downstream Purification of Large Biomolecules

Downstream Purification of Large Biomolecules

Bio-Rad Laboratories | 17-Sep-2018 | Research Study

Our newest strong anion exchange resin provides both high binding capacity and
high recovery, even at high flow rates. A rigid bead complete with...

Related suppliers

Follow us

Products

View more

Webinars